Boston Scientific(BSX), clinical "great success" still faces litigation risks… $14.5 billion acquisition becomes a burden and uncertainty

Boston Scientific (BSX) has achieved a series of clinical successes in the cardiovascular treatment field, continuously enhancing its growth momentum. However, on the other hand, management has been accused of distorting information, leading to divergent market opinions. Despite positive clinical trial results for core medical devices such as “WATCHMAN FLX” and “EKOS,” litigation risks and the burden of large-scale acquisitions are becoming variables that affect future stock price trends.

On the 28th (local time), Boston Scientific announced that its left atrial appendage occluder “WATCHMAN FLX” reached all primary safety and efficacy endpoints at the 36-month time point in the CHAMPION-AF clinical trial. This study involving 3,000 patients with non-valvular atrial fibrillation demonstrated that the device significantly reduced bleeding risk while maintaining similar prevention effects as existing oral anticoagulants (NOACs). Notably, the incidence of serious and clinically significant bleeding not related to surgery was 10.9%, representing a reduction of approximately 45% compared to the existing treatment group (19.0%).

In addition, the overall bleeding incidence, including both surgical and non-surgical events, was only 12.8%, which is 34% lower than current levels, with a surgical success rate as high as 99%. In terms of composite efficacy endpoints, non-inferiority was demonstrated with results of 5.7% versus 4.8%. Industry evaluations indicate that “WATCHMAN FLX” is becoming an alternative that could change the anticoagulant-centered treatment paradigm. Experts in cardiology at the Mayo Clinic stated, “The reduction in bleeding risk is a particularly important indicator for the elderly patient population,” and “its adoption speed will accelerate in real-world prescribing settings.”

The “EKOS” intravascular treatment system announced on the same day is also receiving attention as another growth axis. In the HI-PEITHO clinical trial involving 544 patients with intermediate-risk pulmonary embolism, treatment with “EKOS” in combination with anticoagulants reduced the event rate to 4.0%, improving by approximately 61% compared to the standalone anticoagulant control group recorded at 10.3%. There were no occurrences of intracranial bleeding within 30 days, which also received positive safety evaluations.

Recently, Boston Scientific has continued to push an aggressive expansion strategy. The company is advancing a deal to acquire Penumbra (PEN) for approximately $14.5 billion (around 20.88 trillion KRW) and has included urology treatment device company Valencia Technologies in its product portfolio. The company stated that it aims to achieve $20.74 billion (approximately 28.9 trillion KRW) in sales and adjusted earnings per share (EPS) of $3.06 by 2025, maintaining a double-digit growth momentum.

However, negative issues that stimulate investment sentiment have also emerged. Recently, some investors have filed lawsuits, accusing Boston Scientific’s management of exaggerating its business volume related to electrophysiology procedures in the United States. Although the specific details of the accusations have not been made public, some viewpoints indicate that if the claims are true, it will inevitably harm the company’s reputation.

In this light, while “Boston Scientific” has enhanced its medium to long-term growth expectations through innovative medical device outcomes and aggressive acquisition strategies, it also faces a complex situation of concurrent litigation risks and financial burdens. A Wall Street analyst commented, “Based solely on clinical trial results, it is undoubtedly an industry-leading company, but in the short term, event-driven issues and post-acquisition integration costs could exacerbate stock price volatility.”